The Cannabis Investor Forum is delighted to announce we have officially partnered with Eco Equity for the upcoming event in London this October.
Eco Equity has laid out its blueprint for growth within the cannabis market through the acquisition of a licence from the Zimbabwean government for the cultivation of cannabis for medicinal purposes is only the beginning for this team of ambitious directors.
In an industry full of creative, successful entrepreneurs, Eco Equity made its mark early, and the licence acquisition in Zimbabwe is reflective of the drive and expertise of the company’s directors.
Coming together from different sectors such as finance, media and the cannabis industry itself, the team of directors and consultants understand that CBD and its derivative products could help millions of people recover from illness.
Eco Equity has partnered with the Zimbabwe Ministry of Health to develop, own and operate a medicinal cannabis facility in Zimbabwe with the objective to export the products derived from the facility to Canada, USA and Europe.
Combining research, development, cultivating, growing and manufacturing, Eco Equity’s mission is to advance the medical extracts, related products and sector as a whole and developing products that are safe, effective and affordable for export.
Eco Equity are currently conducting a private funding round to support the growth of their integrated cannabis production and CBD business.
Jonathan Roy, the Director of the Cannabis Investor Forum commented on the partnership:
“We are proud to be working with an innovative British cannabis company that is seeking to put the UK on the map as a hub for global cannabis businesses.”
“Eco Equity represent the entrepreneurial spirit of early stage UK cannabis companies and Eco’s story so far highlights the exciting opportunity for both companies and investors in the sector.”
Jon-Paul Doran, CEO of Eco Equity said:
“We are delighted to be working closely with the Cannabis Investor Forum.”
“Our aim at Eco Equity is to establish ourselves in the sector as a brand known for consistency and quality. We are here to produce an alternative form of medication with the ability to benefit millions of lives.”